Simplifying Ulcerative Colitis Treatment: Evaluating a Single 1600 mg 5-ASA Tablet Regimen in the EASI Trial

Highlight

• The EASI trial tested whether a single 1600 mg 5-ASA tablet improves adherence in ulcerative colitis compared to three 800 mg tablets.
• Adherence rates were comparable between groups, with a trend toward fewer missed doses in the single-tablet group.
• Relapse rates and symptom control did not differ significantly between regimens during 12 months of use.
• The single 1600 mg tablet is a practical alternative that may simplify treatment without compromising efficacy or safety.

Study Background